唑来膦酸对男性骨质疏松的骨密度提升作用  

Efficacy of Zoledronate on Bone Mineral Density for Male Osteoporosis

作　　者：李毅敏[1] 庄华烽[2] 蔡思清[3] 俞海明[2] 王培文[2] 李毅中[2] LI Yi-min;ZHUANG Hua-feng;CAI Si-qing;YU Hai-ming;WANG Pei-wen;LI Yi-zhong(Department of Pharmacy,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Orthopaedics,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Radiology,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院药学部,福建泉州362000 [2]福建医科大学附属第二医院骨科,福建泉州362000 [3]福建医科大学附属第二医院放射科,福建泉州362000

出　　处：《海峡药学》2024年第12期96-99,共4页Strait Pharmaceutical Journal

摘　　要：目的观察真实世界医疗实践中唑来膦酸对男性骨质疏松患者的骨密度提升作用及是否存在性别差异。方法回顾性分析2013~2020年在我院接受唑来膦酸治疗的男性骨质疏松患者的1年骨密度结果,并与同期配对的骨质疏松妇女资料作为对比,比较男性和女性患者各自治疗前与1年后腰椎、股骨颈与总髋骨密度变化,以及男性和女性患者间治疗后骨密度提升情况。统计学方法采用自身前后配对T检验与独立样本t检验。结果共有60例男性骨质疏松患者符合纳入标准,其中54例男性患者具有完整的治疗前后腰椎、股骨颈与总髋骨密度资料。在60例配对绝经后妇女中,58例具有完整的治疗前后腰椎、股骨颈与总髋骨密度资料,治疗前男性与女性患者在年龄及腰椎、股骨颈与总髋的T值无显著差异,唑来膦酸治疗后1年男性与女性的腰椎、股骨颈与总髋的骨密度与T值均获得非常显著的提升,男性腰椎骨密度提升5.9%,股骨颈骨密度提升2%,总髋骨密度提升2.1%。女性腰椎骨密度提升5.4%,股骨颈骨密度提升2.1%,总髋骨密度提升1.7%。男性与女性的各部位骨密度及T值提升幅度均无统计学差异。结论在真实世界实践中,唑来膦酸治疗男性骨质疏松,能显著提升骨密度。OBJECTIVE To observe the efficacy of zoledronate on bone mineral density in the male osteoporosis in the real-world medical practice and to compare the efficacy with the women with postmenopausal osteoporosis.METHODS The change of BMD one year after infusion of zoledronate was retrospectively analyzed in the male patients with osteoporosis in our hospital from 2013 to 2020,and the efficacy of zoledronate in male patients was compared with the women with postmenopausal osteoporosis.BMD at lumbar spine,femoral neck and total hip before treatment and 1 year after treatment of zoledronate were compared respectively in male patients and female patients and between male patients and female patients.Self-paired t-test and t-test were used in statistical analysis.RESULTS Out of 60 male patients included in the study,54 patients had data of BMD at all sites before treatment and 1 year after treatment of zoledronate.Out of 60 paired female patients,58 patients had data of BMD all sites before treatment and 1 year after treatment of zoledronate.No statistical differences in age and T-score at lumbar spine,femoral neck and total hip before treatment were present between male patients and female patients.One year after infusion of zoledronate,male and female patients respectively had significant increase in BMD and T-score at all sites.Male patients had BMD at the lumbar spine increased by 5.9%,BMD at femoral neck by 2%,and BMD at total hip by 2.1%.Female patients had BMD at the lumbar spine increased by 5.5%,BMD at femoral neck by 2.1%,and BMD at total hip by 1.7%.No statistical differences in the magnitude of increased BMD and T-score at all sites after infusion of zoledronate were present between male patients and female patients.CONCLUSION Zoledronate can significantly improve bone mineral density in the treatment of male osteoporosis in the real-world practice.

关 键 词：男性 骨质疏松 唑来膦酸 骨密度 

分 类 号：R969.4[医药卫生—药理学]